CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 334 enrolled
Drug / intervention
Erlotinib +5 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01248247
NCT01248247Phase 2Completed
CompareCT.gov

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

M.D. Anderson Cancer Center·interventional·Posted Nov 25, 2010·Updated Jan 12, 2022

In Brief

A Phase 2 clinical trial evaluating Erlotinib, AZD6244, and 2 other interventions for Lung Cancer. Completed, enrolled 334 participants across 2 sites.

Detailed Summary

Different people have different biomarkers (chemical "markers" in the blood that may be related to your reaction to study drugs). If researchers know about your biomarkers before you receive treatment, they may be able to prescribe a treatment that is better suited to your body's specific needs. The goal of this clinical research study is to learn if drug or drug combinations based on your biomarkers can help to control NSCLC. The safety of these drug combinations will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, National Cancer Institute (NCI), GlaxoSmithKline, Novartis

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2010
Enrollment StartJun 2, 2011
Primary CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 9.5 yearsPosted 15.6 years ago

Interventions

Erlotinibdrug

150 mg by mouth each day of a 28 day cycle.

AZD6244drug

100 mg by mouth daily of a 28 day cycle.

MK-2206drug

100 mg by mouth every week of a 28 day cycle.

Sorafenibdrug

400 mg by mouth twice a day for a 28 day cycle.

Erlotinibdrug

150 mg by mouth daily of a 28 day cycle.

MK-2206drug

135 mg by mouth every week of a 28 day cycle.